Meeting News CoverageVideo

VIDEO: G-POEM promising minimally invasive treatment for refractory gastroparesis

SAN DIEGO — In this exclusive video from DDW 2016, Mouen A. Khashab, MD, associate professor of medicine and director of therapeutic endoscopy at Johns Hopkins Hospital in Baltimore, discusses positive results from a study of gastric peroral endoscopic myotomy.

This minimally invasive treatment for refractory gastroparesis is an “innovative new procedure that we term G-POEM,” Khashab said.

The multicenter trial included 30 patients, in whom all procedures were completed successfully with a mean procedure time of 72 minutes and no major adverse events.

“Eighty-six percent of patients responded very well, which means they were able to eat solid food without nausea or vomiting and without recurrent hospitalization,” Khashab said. Sustained response was observed during follow-up ranging from 3 months to 2.5 years, and no recurrent hospitalizations occurred since the procedure, he added.

“Based on these encouraging results we are currently recruiting patients for a prospective study on G-POEM,” he concluded.

Reference:

Khashab MA, et al. Abstract #Mo2015. Presented at: Digestive Disease Week; May 21-24, 2016; San Diego.

Disclosure: Khashab reports consulting and advisory relationships with Boston Scientific.

SAN DIEGO — In this exclusive video from DDW 2016, Mouen A. Khashab, MD, associate professor of medicine and director of therapeutic endoscopy at Johns Hopkins Hospital in Baltimore, discusses positive results from a study of gastric peroral endoscopic myotomy.

This minimally invasive treatment for refractory gastroparesis is an “innovative new procedure that we term G-POEM,” Khashab said.

The multicenter trial included 30 patients, in whom all procedures were completed successfully with a mean procedure time of 72 minutes and no major adverse events.

“Eighty-six percent of patients responded very well, which means they were able to eat solid food without nausea or vomiting and without recurrent hospitalization,” Khashab said. Sustained response was observed during follow-up ranging from 3 months to 2.5 years, and no recurrent hospitalizations occurred since the procedure, he added.

“Based on these encouraging results we are currently recruiting patients for a prospective study on G-POEM,” he concluded.

Reference:

Khashab MA, et al. Abstract #Mo2015. Presented at: Digestive Disease Week; May 21-24, 2016; San Diego.

Disclosure: Khashab reports consulting and advisory relationships with Boston Scientific.

    See more from Digestive Disease Week